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Abstract Cells of the mononuclear phagocyte lineage fuse
to form multinucleated giant cells and osteoclasts. Several
lines of evidence suggest that P2 receptors, in particular
P2X7, are involved in this process, although P2X7 is not
absolutely required for fusion because P2X7-null mice form
multinucleated osteoclasts. Extracellular ATP may be an
important regulator of macrophage fusion.
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Mononuclear phagocytes fuse to form multinucleated giant
cells in several different contexts. When called upon to
delimit an inert object they cannot consume, macrophages
fuse to become foreign body giant cells and a foreign body
granuloma arises. If the object is an intracellular pathogen
that cannot be completely eradicated when cell-mediated
immunity is activated, mononuclear phagocytes coalesce to
form Langhans giant cells which are morphologically
distinct from those found in foreign body granulomas.
Finally, cells of the mononuclear phagocyte lineage also
form osteoclasts, cells that are responsible for bone
resorption. P2 receptors are highly expressed on mononu-
clear phagocytes, and several investigators have published
data that suggest a role for these receptors in the process of
macrophage fusion.
Proteins involved in multinucleation
Macrophage fusion is poorly understood although several
different molecules have been implicated in this process. A
number of cytokines including interferon (IFN)-+, interleu-
kin (IL)-3, IL-4, IL-6, and IL-13 can induce fusion of
macrophage precursors or cell lines in vitro [1]. Several
plasma membrane molecules have been invoked as medi-
ators of the fusion process, including CD44 [2, 3], SIRP-!
[4], CD47 [5], CD98 [6], and ADAM9 [7]. Perhaps the
protein most convincingly shown to be involved in the
multinucleation process is DC-STAMP, an integral mem-
brane protein first identified in dendritic cells [8]. DC-
STAMP-null mice fail to form multinucleated giant cells or
osteoclasts, and reexpression of DC-STAMP was sufficient
to restore multinucleation [9].
P2X7 and giant cell formation
The first indication that P2 receptors might play a role in
fusion of mononuclear phagocytes was provided by Falzoni
et al., who demonstrated that fusion of human monocyte-
derived macrophages induced by concanavalin A or IFN-+
could be substantially reduced by incubating the cells in
300 μM oxidized ATP (oATP), a treatment which inhibits,
but is not totally specific for, P2X receptors [10]. Further
data supporting a role for P2X7 in fusion of J774 mouse
macrophage-like cells was obtained using J774 variant cell
lines selected for either increased or decreased P2X7
activity, assessed as ATP-induced uptake of the fluorescent
dye Lucifer Yellow [11]. J774 cell lines with increased
P2X7 activity demonstrated spontaneous cell fusion and
multinucleation, while unselected J774 cells and J774 cells
with decreased ATP-induced pore formation did not. In
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with increased ATP-induced pore formation was again
inhibited by preincubation of the cells in medium contain-
ing oATP. It also appeared that under basal conditions the
amount of P2X7 activity, and the degree of spontaneous
multinucleation, was diminished because of spontaneous
release of ATP into the medium. In support of this
conjecture, addition of hexokinase to consume extracellular
ATP resulted in enhanced multinucleation in cultures of
J774 cells with high P2X7 activity.
The development of a monoclonal antibody that recog-
nizes an extracellular epitope of human P2X7 and blocks a
number of different P2X7 activities [12]p r o v i d e da n
opportunity to address the role of P2X7 in giant cell
formation more specifically [13].
When concanavalin A-stimulated human monocyte-
derived macrophages were incubated with this antibody,
formation of multinucleated giant cells was blocked,
although the cells remained capable of forming aggregates.
Immunofluorescence micrographs suggested that P2X7 was
more highly concentrated at sites of interaction between
adjacent cells.
In sum the above experiments with primary mononuclear
cells and cells of the J774 mouse macrophage-like cell line
provide evidence for a role of P2X7 in fusion of mono-
nuclear phagocytes to form multinucleated giant cells. They
leave open the question of the precise role of P2X7 in this
process, whether P2X7 needs to be activated to support the
process of multinucleation, and if so, what the signaling
molecule or counterreceptor is. What is the role of ATP
itself in this process? Ambient ATP in the extracellular
environment appeared actually to be inhibitory, as enzy-
matic hydrolysis of ATP enhanced fusion, but it is still
possible that ATP may activate P2X7 in the context of a
delimited space that is formed after cell-cell contact.
Monocytes harvested from patients with sarcoidosis, a
disease characterized by granuloma formation, were more
susceptible to the cytolytic effect of BzATP [14]. These
data from a granulomatous disorder of humans may
indicate a correlation between giant cell formation and
P2X7 expression.
P2X7 and osteoclast formation
In addition to forming immune and foreign body giant cells,
cells of the mononuclear phagocyte lineage fuse to form
osteoclasts, multinucleated cells that resorb bone. Osteo-
clasts function in concert with osteoblasts, fibroblast
lineage cells which deposit new bone. Osteoblasts and
osteoclasts must coordinate their activity for normal bone
remodeling and the maintenance of skeletal integrity, and
P2 receptors may be involved in several aspects of this
coordinated activity.
Osteoclast formation is perhaps the most thoroughly
investigated form of macrophage fusion and multinuclea-
tion for several reasons. The generation of multinucleated
osteoclasts is better defined than is generation of other
monocyte-derived multinucleated giant cells. Thus, while a
number of cytokines including tumor necrosis factor (TNF),
IFN-+, IL-3, IL-4, and IL-6 may play a role in giant cell
formation, it is clear that in addition to m-CSF, only
RANKL is necessary for osteoclast differentiation and
multinucleation in vitro. While other multinucleated giant
cells are formed in response to invading pathogens or
foreign bodies, osteoclasts are generated in the course of
normal bone homeostasis. Their function is relatively
straightforward to assess in vitro and significant impairment
of osteoclast function results in osteopetrosis, in which
bone morphology is abnormal, and failure of bone marrow
cavity formation occurs and is readily assessed in living
animals by X-ray studies and by histomorphometry of
explanted bone. Osteopetrosis leads to death because of
failure of hematopoiesis. Striking examples of osteopetrosis
due to failure of osteoclast formation have been described
in mice in which m-CSF or RANKL signaling has been
disrupted. Extracellular nucleotides cause calcium rises in
osteoclasts, both via calcium influx and release of calcium
stores [15]. P2X2, P2X4, and P2X7 have been identified in
rat osteoclasts [16]; P2Y2 is expressed but does not localize
to the cell surface and does not appear to be functional [17].
Gartland et al. performed an analysis of P2X7 expression in
vivo and in human osteoclastic cells derived by in vitro
culture of human peripheral blood mononuclear cells with
m-CSF and RANKL and demonstrated P2X7 throughout at
various stages in osteoclast differentiation using a blocking
extracellular monoclonal antibody [18]. This antibody
inhibited the formation of multinucleated osteoclasts from
human peripheral blood monocytes. In the presence of this
antibody, m-CSF- and RANKL-treated cells expressed
tartrate-resistant acid phosphatase, a phenotypic marker
for osteoclast differentiation, in spite of the fact that they
did not become multinucleated. Osteoclast resorptive
activity, assessed on dentine discs, was also markedly
inhibited by antibody treatment.
P2X7 gene-deleted mice have been generated, are fertile,
and appear relatively normal [19]. Bone formation and
resorption in these mice at 2 and 9 months of age is
abnormal [20]. Although the femurs are normal in length,
they have a significant reduction in periosteal circumfer-
ence. There is also a decrease in cortical bone content and
periosteal bone formation. Furthermore, bone resorption is
increased and osteoclasts appeared normal although in-
creased in number. Thus, activity of the osteoclast
54 Purinergic Signalling (2007) 3:53–57compartment appears to be enhanced in the absence of
P2X7.
Gartland et al. specifically examined the ability of
mononuclear precursor cells to generate multinucleated
osteoclasts in vivo and in vitro in the P2X7-null mice and
confirmed that multinucleation of osteoclasts did indeed
occur in both instances [21]. Cells from P2X7-null cells
were able to undergo plasma membrane permeabilization in
response to maitotoxin, which operates a pore with
characteristics similar to those induced by P2X7 ligation.
It had been previously proposed that P2X7 may not be itself
the ATP-induced pore, but may instead activate a pore that
also can be activated by maitotoxin [22]. Thus, the above
findings may suggest that while P2X7 may not be an
integral part of the fusion machinery, it may promote
osteoclast fusion by activating a fusogenic pore-forming
plasma membrane protein that is currently unidentified.
The bone phenotype seen in the P2X7-null mouse may
or may not be due to absence of P2X7 from osteoclasts,
since osteoblasts also express P2X7. Osteoblastic cell lines
[23–25], rat primary osteoblasts [26], and primary cultures
of human osteoblasts [24] all express P2 receptors. Several
members of both P2X and P2Y classes are present on the
surface of human and rat osteoblastic cells, in particular,
P2Y2, P2X2, and P2X5 [27–29]. P2X7 expression and
function has also been demonstrated in murine osteoblasts
[30] and osteoblast P2X7 activity is required for normal
skeletal response to mechanical stress [31].
Downregulation of P2X7 and inhibition of osteoclast
formation in RAW cells
RAW 264.7 (RAW) is a mouse macrophage-like cell line
that forms multinucleated osteoclastic cells in vitro in the
presence of RANKL. This model is quite reproducible in
vitro. When RANKL is added to RAW cells, one sees
almost no multinucleation during days 1–3, but between
days 3 and 4 widespread cell fusion and multinucleation
occurs. Although cells remain unfused during the first
3 days, they acquire a number of osteoclast markers, such
as tartrate-resistant acid phosphatase. Thus, RAW cells
cannot only be used as a model for osteoclast fusion, but
allow one to distinguish between osteoclast differentiation,
as assessed by acquisition of phenotypic markers, and
osteoclast fusion. RAW cells have been used to explore the
relationship between P2 receptors, extracellular ATP, and
osteoclast fusion [32]. In some macrophage cell lines,
incubation of cells expressing P2X7 in ATP for long periods
of time selects cells that do not express P2X7-mediated pore
formation. When RAW cells were incubated in medium
containing 2 mM ATP overnight, some of the cells died but
the surviving cells did not become permeable to the
fluorescent dye YO-PRO when incubated in ATP (ATP-R
cells). This phenotype was reversible: if the cells were
subsequently incubated in medium without ATP overnight,
they regained ATP-induced permeability to YO-PRO (ATP-S
cells). The mechanism for this reversible ATP resistance was
Fig. 1 Prolonged incubation in
ATP prevents osteoclast forma-
tion but not acquisition of TRAP
positivity. RAW cells made re-
sistant to the permeabilizing
effect of extracellular ATP by
prolonged incubation in ATP
(RAW ATP-R) or RAW cells
that regained ATP sensitivity
after removal of ATP (RAW
ATP-S) were incubated in me-
dium with or without RANKL
for 4 days, fixed, and stained for
tartrate-resistant acid phospha-
tase (TRAP). RAW ATP-S cells
formed multinucleated osteo-
clasts in response to RANKL,
but RAW ATP-R cells did not.
Nevertheless, RAW ATP-R cells
became TRAP positive, indicat-
ing that osteoclast differentiation
was not totally inhibited in these
cells
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maintained in ATP expressed as much P2X7 protein as did
untreated cells, but they expressed no P2X7 on the cell
surface. Thus, in untreated RAW cells and in ATP-S cells
most of the P2X7 is in an intracellular vesicular pool, but
roughly 10% localized to the cell surface. In ATP-R cells,
this plasma membrane pool of P2X7 vanishes.
Unlike untreated RAW cells, when ATP-R cells are
incubated in medium containing RANKL to induce
osteoclastogenesis, cell fusion and giant cell formation is
not detected (Fig. 1). Although the ATP-R cells remain
unfused, they do become positive for TRAP and other
markers of osteoclast differentiation, suggesting that the
defect in ATP-R cells is related to the fusion process itself
and not to the ability of these cells to undergo osteoclast
differentiation, and probably occurs at a late step in the
process of osteoclastogenesis. Supporting this hypothesis, if
ATP is removed from the medium 72 h after addition of
RANKL, cell fusion occurs in the next 24 h. These
experiments demonstrate that prolonged incubation of
RAW cells in ATP induces internalization of P2X7 and
prevents cell fusion and multinucleation. Incubation of
RAW cells in BzATP, but not adenosine diphosphate
(ADP), uridine diphosphate (UDP), or uridine triphosphate
(UTP), yielded similar results, suggesting that P2X7 or
another P2X receptor is involved in inhibition of osteoclast
fusion in this model system.
Given that P2X7-null mice form multinucleated osteo-
clasts, several possible interpretations of the above data
arise. It is possible that P2X7 is indeed directly involved in
mononuclear cell fusion, but that its role in mononuclear
cell fusion can be taken over by other receptors in its
absence. Perhaps other P2X receptors can fulfill this role,
and preliminary data demonstrate that RAW cells express
P2X4 and P2X6 in addition to P2X7. In this context, the fact
that P2X7 monoclonal antibodies inhibit fusion may
indicate either that these antibodies affect other P2X7
receptors, that the other receptors that mediate fusion are
not present or upregulated in this situation, or that the
presence of P2X7-P2X7 antibody complexes on the cell
surface exerts an inhibitory effect on the process of fusion.
Another possibility is that P2X7 plays a less direct role in
the fusion process, perhaps by influencing a signaling
cascade that is involved in the fusion process, and which
may involve one or more of the other proteins that have
been implicated in mononuclear cell fusion.
The above RAW cell experiments may suggest that
extracellular ATP itself is an important regulator of multi-
nucleation, and the pharmacological data imply that this
occurs through activation of P2X receptors. To determine
whether the inhibitory effect of prolonged incubation in
extracellular ATP requires the presence of P2X7,A T P
incubation experiments similar to the RAW cell experi-
ments described above were performed with bone marrow
mononuclear cells derived from P2X7-null mice (Hiken and
Steinberg, manuscript in preparation). These experiments
could not be performed with cells from wild-type mice,
because prolonged exposure to ATP killed the cells.
However, when cells from P2X7-null mice were incubated
in 2 mM ATP, most cells survived. Bone marrow cells from
either wild-type or P2X7-null mice incubated in medium
containing m-CSF and RANK formed TRAP-positive
multinucleated osteoclasts. In contrast, cells from P2X7-
null mice that had been incubated in ATP did not fuse,
although they did acquire TRAP positivity. Thus, prolonged
exposure of osteoclast precursors to ATP inhibits osteoclast
fusion by a process that does not absolutely require P2X7.
Prolonged exposure of RAW cells to ATP downregulated
P2X7, and it seems reasonable to speculate that other P2
receptors are similarly removed from the plasma membrane
by incubation of cells in ATP.
Conclusions
Although there is considerable interest in defining the
mechanism of macrophage multinucleation, this process
remains poorly defined. The recent demonstration that DC-
STAMP-null mice are unable to form multinucleated giant
cells constitutes a major advance in this field, and the
relationship between DC-STAMP and P2 receptors remains
to be determined. Although much evidence suggests that
P2X7 influences the multinucleation process, P2X7 is not
absolutely required for osteoclast formation, and it is
unclear whether other P2X receptors are involved in giant
cell formation and if they can compensate for the lack of
P2X7. Extracellular ATP alters giant cell formation in vitro,
as consumption of extracellular ATP enhances giant cell
formation and prolonged incubation in extracellular ATP
inhibits osteoclast fusion. These observations suggest that
extracellular ATP may be an important modulator of giant
cell formation and osteoclastogenesis in vivo.
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